According to the recent American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) clinical practice guidelines, HBsAg and anti-HBc testing should be performed in all patients before initiation of any immunosuppressive, cytotoxic, or immunomodulatory therapy (21, 22). This evidence concerns the gene KRT88P and liver disorder.